DeLong Mark Jeffrey 4
4 · Apellis Pharmaceuticals, Inc. · Filed Jan 23, 2025
Insider Transaction Report
Form 4
DeLong Mark Jeffrey
Chief Business & Strat Officer
Transactions
- Sale
Common Stock
2025-01-22$30.43/sh−1,396$42,474→ 84,673 total
Footnotes (1)
- [F1]This represents shares sold to cover tax withholding on the Restricted Stock Units released on January 21, 2025.